FDA Rejects GSK’s Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use … – Lung Disease News


Lung Disease News

FDA Rejects GSK's Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use
Lung Disease News
GSK Incruse Ellipta COPD The U.S. Food and Drug Administration (FDA) ruled against the use of GlaxoSmithKline's new drug combination Breo Ellipta in asthma patients between the ages of 12 and 17. However, the Pulmonary-Allergy Drugs Advisory …

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.